Statin therapy in nephrotic syndrome Patients with nephrotic syndrome are believed to have an increased risk of developing coronary heart disease1 although existing evidence supporting this association has not been persuasive2. The efficacy of HMG-CoA reductase inhibitors in the treatment of hyperlipidaemia secondary to nephrotic syndrome, as illustrated by Dr Revai and Dr Harmos' case report (January 1999 JRSM, pp. 23-24), is well established3'4. In their case of minimal change nephropathy, however, treatment of secondary hyperlipidaemia with simvastatin may not be warranted particularly since the primary nephropathy went into complete remission following steroids and chemotherapy. It would seem logical to consider statin therapy in treatmentresistant nephropathy when the secondary hyperlipidaemia is likely to persist. This treatment-resistant group is more likely to develop renal impairment with resultant hypertension3, which further increases the cardiovascular risk. 
